Monday, April 22, 2013
Therapeutics Inc. is developing synthetic sodium channel blockers for
pain that have a different chemical scaffold and better characterized binding
site than competing molecules. The result, according to the company, should be
advantages in potency, selectivity and solubility.
SiteOne's sodium channel
platform is based on marine guanidinium toxins, which include tetrodotoxins,
saxitoxins and gonyautoxins. These small molecules are used as pharmacological
tools and have potent activity against voltage-gated sodium channels. The
problem is that the difference between a therapeutic and a toxic dose of
guanidinium toxins is small.